• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    11/12/24 10:32:12 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 KORRO BIO INC COMMON STOCK Cusip #500946108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #500946108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 579,478 Item 6: 0 Item 7: 579,563 Item 8: 0 Item 9: 579,563 Item 11: 6.232% Item 12: HC Cusip #500946108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 579,563 Item 8: 0 Item 9: 579,563 Item 11: 6.232% Item 12: IN Item 1(a). Name of Issuer: KORRO BIO INC Item 1(b). Address of Issuer's Principal Executive Offices: ONE KENDALL SQUARE. BUILDING 600-700, SUITE 6-401 CAMBRIDGE, MA 02139 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 500946108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 579,563 (b) Percent of Class: 6.232% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 579,563 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KORRO BIO INC. No one other person's interest in the COMMON STOCK of KORRO BIO INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of KORRO BIO INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $KRRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    3/13/2026$23.00Mkt Perform → Outperform
    Raymond James
    2/17/2026Mkt Perform → Outperform
    William Blair
    1/29/2026$30.00Neutral → Overweight
    Piper Sandler
    1/29/2026$15.00Neutral → Buy
    Chardan Capital Markets
    1/29/2026$20.00Neutral → Buy
    H.C. Wainwright
    1/28/2026$21.00Neutral → Overweight
    Cantor Fitzgerald
    1/28/2026$22.00Perform → Outperform
    Oppenheimer
    11/13/2025$8.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Behbahani Ali was granted 207,100 shares (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:10 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:15 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:13 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:15 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:13 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Yang Rick bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:16 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Korro Bio upgraded by Raymond James with a new price target

    Raymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00

    3/13/26 8:41:33 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by William Blair

    William Blair upgraded Korro Bio from Mkt Perform to Outperform

    2/17/26 7:51:08 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Korro Bio from Neutral to Overweight and set a new price target of $30.00

    1/29/26 6:58:39 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    SEC Filings

    View All

    SEC Form 424B5 filed by Korro Bio Inc.

    424B5 - Korro Bio, Inc. (0001703647) (Filer)

    3/20/26 5:03:09 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Korro Bio Inc.

    S-3 - Korro Bio, Inc. (0001703647) (Filer)

    3/13/26 5:05:49 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Korro Bio Inc.

    10-K - Korro Bio, Inc. (0001703647) (Filer)

    3/12/26 4:12:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on Decem

    3/12/26 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Present at the TD Cowen 46th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar's presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET. About Korro Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevale

    2/25/26 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Host Virtual Analyst Day on January 27, 2026

    - Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a urea cycle disorder (UCD). Korro

    1/20/26 8:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    View All

    Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    4/1/25 7:30:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    11/12/24 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 7:54:42 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 3:04:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care